Nexstim logo

The decisions of the Board of Directors, 28 march 2017

28 March 2017

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces that the Board of Directors of Nexstim Plc. has today, in the meeting that took place after the Annual General Meeting, elected the members of the Board Committees as follows:

  The chairman of the Audit Committee shall be Juliet Thompson and the members shall be Rohan J. Hoare and Tomas Holmberg.

 

The chairman of the Remuneration committee shall be Ken Charhut and the members shall be Rohan J. Hoare and Martin Jamieson.

The chairman of the Nomination Committee shall be Sami Tuhkanen.

 

NEXSTIM PLC

Martin Jamieson, chairman and CEO

 

Further information is available on the website www.nexstim.com or by contacting:

 

Nexstim                                                                                                                                    +447715163942

Martin Jamieson, Chief Executive Officer                                           martin.jamieson@nexstim.com

                                                                                                                                                                                

UB Securities Oy (Certified Adviser)                                                                         +358 (0)9 2538 0246

 

Citigate Dewe Rogerson                                                                                               +44 (0)207 2821066

Katja Stout                                                                                                        katja.stout@citigatedr.co.uk

 

About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

 

Back to Press Releases

Sorry, there are no fact sheets available. Please check back soon.

Follow us

linkedin

Twitter
YouTube